FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176750854> ?p ?o ?g. }

• W3176750854 endingPage "919" @default.
• W3176750854 startingPage "914" @default.
• W3176750854 abstract "To evaluate the effect of AMD3100 treatment to cholangiocarcinoma by analyzing the relationship between them, and provide experimental evidence for whether AMD3100 can become a clinical treatment drug for cholangiocarcinoma.Cholangiocarcinoma RBE cell lines were used in this study. MTT cell proliferation test was used for evaluating the effect of gemcitabine and AMD3100 to cell. CXCR4, N-cadherin, VEGF-C and MMP-9 were detect by RT-PCR and western. Transwell was used for evaluating the invasion effect.We demonstrated that as the concentration of gemcitabine increasing from 0.33, 3.33 to 33.33 uM, the cell survival rate was 76.65%, 71.40%, 52.25%, respectively. RT-PCR and Western blot that gemcitabine could affect the expression of CXCR4 protein and the level of mRNA transcription in a dose-dependent manner. N-cadherin VEGF-C, MMP-9 mRNA transcription level showed a significant upward trend in gemcitabine group. In Transwell test, the number of cells in the gemcitabine group was significantly higher than that in the no-medication group (p < .05), the AMD3100 group and the combination group of gemcitabine and AMD3100, the difference between the no-medication group and the AMD3100 monotherapy group was not significant, and the combination group was between them.This study showed that gemcitabine significantly inhibited the growth of cholangiocarcinoma RBE cells in a dose-dependent manner, and gemcitabine can affect the expression of CXCR4, N-cadherin, VEGF-C, MMP-9 protein and mRNA. Cell invasion and metastasis-related factors decreased after AMD3100 combined with gemcitabine." @default.
• W3176750854 created "2021-07-05" @default.
• W3176750854 creator A5002244546 @default.
• W3176750854 creator A5008091677 @default.
• W3176750854 creator A5019409553 @default.
• W3176750854 creator A5020597164 @default.
• W3176750854 creator A5054620758 @default.
• W3176750854 creator A5084887768 @default.
• W3176750854 creator A5090822861 @default.
• W3176750854 date "2021-06-24" @default.
• W3176750854 modified "2023-09-23" @default.
• W3176750854 title "The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis" @default.
• W3176750854 cites W1510049477 @default.
• W3176750854 cites W1867767808 @default.
• W3176750854 cites W1879421870 @default.
• W3176750854 cites W1974376253 @default.
• W3176750854 cites W1980595140 @default.
• W3176750854 cites W1984908936 @default.
• W3176750854 cites W1990196941 @default.
• W3176750854 cites W2058554403 @default.
• W3176750854 cites W2060626200 @default.
• W3176750854 cites W2064830801 @default.
• W3176750854 cites W2071502249 @default.
• W3176750854 cites W2072178451 @default.
• W3176750854 cites W2103562758 @default.
• W3176750854 cites W2107277218 @default.
• W3176750854 cites W2112347626 @default.
• W3176750854 cites W2115261608 @default.
• W3176750854 cites W2115475846 @default.
• W3176750854 cites W2116992727 @default.
• W3176750854 cites W2147460365 @default.
• W3176750854 cites W2176078674 @default.
• W3176750854 cites W2207537447 @default.
• W3176750854 cites W2416032491 @default.
• W3176750854 cites W2516429553 @default.
• W3176750854 cites W2520398051 @default.
• W3176750854 cites W2549745345 @default.
• W3176750854 cites W2578371359 @default.
• W3176750854 doi "https://doi.org/10.1080/00365521.2021.1906944" @default.
• W3176750854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34165373" @default.
• W3176750854 hasPublicationYear "2021" @default.
• W3176750854 type Work @default.
• W3176750854 sameAs 3176750854 @default.
• W3176750854 citedByCount "1" @default.
• W3176750854 countsByYear W31767508542023 @default.
• W3176750854 crossrefType "journal-article" @default.
• W3176750854 hasAuthorship W3176750854A5002244546 @default.
• W3176750854 hasAuthorship W3176750854A5008091677 @default.
• W3176750854 hasAuthorship W3176750854A5019409553 @default.
• W3176750854 hasAuthorship W3176750854A5020597164 @default.
• W3176750854 hasAuthorship W3176750854A5054620758 @default.
• W3176750854 hasAuthorship W3176750854A5084887768 @default.
• W3176750854 hasAuthorship W3176750854A5090822861 @default.
• W3176750854 hasConcept C121608353 @default.
• W3176750854 hasConcept C126322002 @default.
• W3176750854 hasConcept C129470790 @default.
• W3176750854 hasConcept C13373296 @default.
• W3176750854 hasConcept C143998085 @default.
• W3176750854 hasConcept C1491633281 @default.
• W3176750854 hasConcept C170493617 @default.
• W3176750854 hasConcept C185592680 @default.
• W3176750854 hasConcept C2779013556 @default.
• W3176750854 hasConcept C2780258809 @default.
• W3176750854 hasConcept C502942594 @default.
• W3176750854 hasConcept C54355233 @default.
• W3176750854 hasConcept C55493867 @default.
• W3176750854 hasConcept C71924100 @default.
• W3176750854 hasConcept C81885089 @default.
• W3176750854 hasConcept C86803240 @default.
• W3176750854 hasConceptScore W3176750854C121608353 @default.
• W3176750854 hasConceptScore W3176750854C126322002 @default.
• W3176750854 hasConceptScore W3176750854C129470790 @default.
• W3176750854 hasConceptScore W3176750854C13373296 @default.
• W3176750854 hasConceptScore W3176750854C143998085 @default.
• W3176750854 hasConceptScore W3176750854C1491633281 @default.
• W3176750854 hasConceptScore W3176750854C170493617 @default.
• W3176750854 hasConceptScore W3176750854C185592680 @default.
• W3176750854 hasConceptScore W3176750854C2779013556 @default.
• W3176750854 hasConceptScore W3176750854C2780258809 @default.
• W3176750854 hasConceptScore W3176750854C502942594 @default.
• W3176750854 hasConceptScore W3176750854C54355233 @default.
• W3176750854 hasConceptScore W3176750854C55493867 @default.
• W3176750854 hasConceptScore W3176750854C71924100 @default.
• W3176750854 hasConceptScore W3176750854C81885089 @default.
• W3176750854 hasConceptScore W3176750854C86803240 @default.
• W3176750854 hasIssue "8" @default.
• W3176750854 hasLocation W31767508541 @default.
• W3176750854 hasLocation W31767508542 @default.
• W3176750854 hasOpenAccess W3176750854 @default.
• W3176750854 hasPrimaryLocation W31767508541 @default.
• W3176750854 hasRelatedWork W1498406570 @default.
• W3176750854 hasRelatedWork W1648215019 @default.
• W3176750854 hasRelatedWork W1966037124 @default.
• W3176750854 hasRelatedWork W2041752550 @default.
• W3176750854 hasRelatedWork W2259137911 @default.
• W3176750854 hasRelatedWork W2362184876 @default.
• W3176750854 hasRelatedWork W2437839733 @default.
• W3176750854 hasRelatedWork W2808192109 @default.

• next